Abbott Laboratories (ABT) EBT (2009 - 2026)

Abbott Laboratories has disclosed EBT across 18 years of filings, most recently posting $1.5 billion for Q2 2026.

• In Q2 2026, EBT fell 29.12% year-over-year to $1.5 billion; the TTM figure through Jun 2026 stood at $7.5 billion (down 4.9% YoY), while the FY2025 annual figure was $8.5 billion, up 20.72% from the prior year.
• EBT came in at $1.5 billion for Q2 2026 at Abbott Laboratories, up from $1.4 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• Average EBT over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2022.
• Year-over-year, EBT jumped 74.48% in 2022 and slumped 45.69% in 2023.
• Over 5 years, EBT stood at $1.3 billion in 2022, then jumped by 35.98% to $1.8 billion in 2023, then climbed by 13.09% to $2.0 billion in 2024, then advanced by 16.16% to $2.4 billion in 2025, then slumped by 35.37% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent EBT figures were $1.5 billion in Q2 2026, $1.4 billion in Q1 2026, and $2.4 billion in Q4 2025.